Cann Group (ASX:CAN) ROE % Adjusted to Book Value: 816.80% (As of Dec. 2025)


What is Cann Group ROE % Adjusted to Book Value?

Cann Group ASX:CAN -25.00% ROE % Adjusted to Book Value is 816.80% as of Dec. 2025. The stock has 7 warning signs investors should review.

Cann Group's ROE % for the quarter that ended in Dec. 2025 was 334.89%. Cann Group's PB Ratio for the quarter that ended in Dec. 2025 was 0.41. Cann Group's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 816.80%.

Cann Group ROE % Adjusted to Book Value Related Terms

Cann Group ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Cann Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cann Group ROE % Adjusted to Book Value Chart

Cann Group Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only -31.87 -26.27 -59.34 -159.14 0.00

Cann Group Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.06 -261.16 -65.04 0.00 816.80

ASX:CAN vs ZTS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cann Group ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cann Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cann Group's ROE % Adjusted to Book Value falls into.


Cann Group ROE % Adjusted to Book Value Calculation

Cann Group's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-400.95% / N/A
=N/A

Cann Group's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=334.89% / 0.41
=816.80%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 816.80% mean?
Cann Group (ASX:CAN) has a ROE % Adjusted to Book Value of 816.80% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cann Group and its competitors.
Is Cann Group's ROE % Adjusted to Book Value too high?
Cann Group's current ROE % Adjusted to Book Value is 816.80%.
How does Cann Group's ROE % Adjusted to Book Value compare to ZTS?
Cann Group's ROE % Adjusted to Book Value of 816.80% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cann Group and its competitors. Cann Group's current ROE % Adjusted to Book Value is 816.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 85% below its estimated fair value. The current ROE % Adjusted to Book Value is 816.80%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current ROE % Adjusted to Book Value is 816.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cann Group Business Description

Other Exchanges CNGGF:USA
Address 262-276 Lorimer Street, Ground Floor, Port Melbourne, VIC, AUS, 3207
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.